Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype.

Thrombosis and haemostasis - 1 Apr 2005

Voora Deepak, Eby Charles, Linder Mark W, Milligan Paul E, Bukaveckas Bonny L, McLeod Howard L, Maloney William, Clohisy John, Burnett R Steven, Grosso Leonard, Gatchel Susan K, Gage Brian F

Abstract excerpt

Cytochrome P-450 2C9 (CYP2C9) polymorphisms (CYP2C9*2 and CYP2C9*3) reduce the clearance of warfarin, increase the risk of bleeding, and prolong the time to stable dosing. Whether prospective use of a retrospectively developed algorithm that incorporates CYP2C9 genotype and nongenetic factors can ameliorate the propensity to bleeding and delay in achieving a stable warfarin dose is unknown. We initiated warfarin...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Algorithms
Share to Aryl Hydrocarbon Hydroxylases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C9

Share to Hemorrhage

Share to International Normalized Ratio

Share to Pharmacogenetics

Share to Predictive Value of Tests

Share to Warfarin

Source

Identifiers

PMID: 15841315
DOI: 10.1160/TH04-08-0542

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype.PMID 15841315Read ↗

Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype.Semantic proximity Read ↗

Genetic-based dosing in orthopedic patients beginning warfarin therapy.Semantic proximity Read ↗

CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study.Semantic proximity Read ↗

Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose.Semantic proximity Read ↗

Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of WarfarinSemantic proximity Read ↗

Pharmacogenetics in warfarin therapySemantic proximity Read ↗

The largest prospective warfarin-treated cohort supports genetic forecasting.Semantic proximity Read ↗

A randomized trial of genotype-guided dosing of warfarin.Semantic proximity Read ↗

The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin.Semantic proximity Read ↗

Warfarin PharmacogeneticsSemantic proximity Read ↗

Warfarin Dosing According to the Genotype-guided Algorithm is Most Beneficial in Patients With Atrial Fibrillation: A Randomized Parallel Group Trial.Semantic proximity Read ↗

Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.